Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802658837> ?p ?o ?g. }
- W2802658837 abstract "Alkali burn is one of the main causes of corneal injury. The inflammation and neovascularization caused by alkali burns aggravate corneal damage, resulting in loss of vision. The aim of the present study was to evaluate the efficacy of xanthatin in the treatment of alkali burn‑induced inflammation and neovascularization. A CCK‑8 assay was used to detect the effects of different concentrations of xanthatin on the proliferation of human umbilical vein endothelial cells (HUVECs). The effects of xanthatin on the migration of HUVECs and the ability of lumen formation were examined using a scratch test and lumen formation assay, respectively. A total of 60 Sprague‑Dawley rats were randomly divided into two groups to establish a corneal alkali burn model, and were treated with PBS and xanthatin eye drops four times a day. A slit lamp microscope recorded changes of the cornea at 0, 4, 7, 10 and 14 days, and the inflammatory indices of the cornea and the neovascular area were evaluated. The expression levels of vascular endothelial growth factor (VEGF) and pigment epithelium‑derived factor (PEDF) in the cornea under different treatment conditions were detected using immunofluorescence and western blot analysis. In order to investigate the mechanism of xanthatin on the inhibition of inflammation and neovascularization, HUVECs were treated with xanthatin and PBS following VEGF treatment. The subcellular localization of signal transducer and activator of transcription 3 (STAT3) was detected using immunofluorescence. The expression levels of VEGF receptor 2 (VEGFR2), STAT3, phosphoinositide 3‑kinase (PI3K) and Akt were detected using western blot analysis. The results revealed that xanthatin inhibited the proliferation of HUVECs in a concentration‑dependent manner. The migration ability and lumen‑forming ability of the HUVECs were also inhibited by xanthatin. Slit lamp microscopy showed that the inflammatory index and the area of neovascularization in the xanthatin‑treated group were significantly reduced, compared with those in the PBS treatment group. The xanthatin treatment group exhibited a lower protein expression level of VEGF and increased protein expression level of PEDF, compared with the PBS treatment group. In the VEGF‑treated HUVECs, xanthatin significantly decreased the expression levels of p‑VEGFR2, phosphorylated (p‑)STAT3, p‑PI3K and p‑Akt. In conclusion, the present study confirmed that xanthatin inhibited corneal neovascularization and inflammation in the alkali burn model, elucidating the underlying mechanisms involved in its protective effects. Therefore, xanthatin may be a novel drug for the treatment of corneal alkali burn." @default.
- W2802658837 created "2018-05-17" @default.
- W2802658837 creator A5007123441 @default.
- W2802658837 creator A5015807561 @default.
- W2802658837 creator A5032007999 @default.
- W2802658837 creator A5033838347 @default.
- W2802658837 creator A5041499290 @default.
- W2802658837 creator A5052895830 @default.
- W2802658837 creator A5053759817 @default.
- W2802658837 creator A5056527336 @default.
- W2802658837 creator A5061076734 @default.
- W2802658837 creator A5074953376 @default.
- W2802658837 date "2018-04-30" @default.
- W2802658837 modified "2023-10-09" @default.
- W2802658837 title "Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway" @default.
- W2802658837 cites W142237715 @default.
- W2802658837 cites W1921973844 @default.
- W2802658837 cites W1941356957 @default.
- W2802658837 cites W1966374553 @default.
- W2802658837 cites W1967663251 @default.
- W2802658837 cites W1967756582 @default.
- W2802658837 cites W1973918329 @default.
- W2802658837 cites W1978981032 @default.
- W2802658837 cites W1981360283 @default.
- W2802658837 cites W1985147506 @default.
- W2802658837 cites W1986355310 @default.
- W2802658837 cites W2009055235 @default.
- W2802658837 cites W2009109135 @default.
- W2802658837 cites W2013839411 @default.
- W2802658837 cites W2015781499 @default.
- W2802658837 cites W2023453327 @default.
- W2802658837 cites W2025242477 @default.
- W2802658837 cites W2030627242 @default.
- W2802658837 cites W2032623624 @default.
- W2802658837 cites W2038451782 @default.
- W2802658837 cites W2070696205 @default.
- W2802658837 cites W2077129920 @default.
- W2802658837 cites W2101076870 @default.
- W2802658837 cites W2108542007 @default.
- W2802658837 cites W2110651230 @default.
- W2802658837 cites W2144921938 @default.
- W2802658837 cites W2146484675 @default.
- W2802658837 cites W2158047405 @default.
- W2802658837 cites W2166156136 @default.
- W2802658837 cites W2170723552 @default.
- W2802658837 cites W2172140258 @default.
- W2802658837 cites W2181784365 @default.
- W2802658837 cites W2188914115 @default.
- W2802658837 cites W2424654094 @default.
- W2802658837 cites W2598230851 @default.
- W2802658837 cites W1976566805 @default.
- W2802658837 doi "https://doi.org/10.3892/ijmm.2018.3646" @default.
- W2802658837 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6034915" @default.
- W2802658837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29717775" @default.
- W2802658837 hasPublicationYear "2018" @default.
- W2802658837 type Work @default.
- W2802658837 sameAs 2802658837 @default.
- W2802658837 citedByCount "8" @default.
- W2802658837 countsByYear W28026588372018 @default.
- W2802658837 countsByYear W28026588372019 @default.
- W2802658837 countsByYear W28026588372020 @default.
- W2802658837 countsByYear W28026588372021 @default.
- W2802658837 countsByYear W28026588372022 @default.
- W2802658837 countsByYear W28026588372023 @default.
- W2802658837 crossrefType "journal-article" @default.
- W2802658837 hasAuthorship W2802658837A5007123441 @default.
- W2802658837 hasAuthorship W2802658837A5015807561 @default.
- W2802658837 hasAuthorship W2802658837A5032007999 @default.
- W2802658837 hasAuthorship W2802658837A5033838347 @default.
- W2802658837 hasAuthorship W2802658837A5041499290 @default.
- W2802658837 hasAuthorship W2802658837A5052895830 @default.
- W2802658837 hasAuthorship W2802658837A5053759817 @default.
- W2802658837 hasAuthorship W2802658837A5056527336 @default.
- W2802658837 hasAuthorship W2802658837A5061076734 @default.
- W2802658837 hasAuthorship W2802658837A5074953376 @default.
- W2802658837 hasBestOaLocation W28026588371 @default.
- W2802658837 hasConcept C104317684 @default.
- W2802658837 hasConcept C118487528 @default.
- W2802658837 hasConcept C142724271 @default.
- W2802658837 hasConcept C167734588 @default.
- W2802658837 hasConcept C185592680 @default.
- W2802658837 hasConcept C203014093 @default.
- W2802658837 hasConcept C2776415932 @default.
- W2802658837 hasConcept C2776882836 @default.
- W2802658837 hasConcept C2776914184 @default.
- W2802658837 hasConcept C2777025900 @default.
- W2802658837 hasConcept C2777844972 @default.
- W2802658837 hasConcept C2778271429 @default.
- W2802658837 hasConcept C2778923194 @default.
- W2802658837 hasConcept C2780394083 @default.
- W2802658837 hasConcept C502942594 @default.
- W2802658837 hasConcept C52237779 @default.
- W2802658837 hasConcept C55493867 @default.
- W2802658837 hasConcept C62478195 @default.
- W2802658837 hasConcept C71924100 @default.
- W2802658837 hasConcept C75217442 @default.
- W2802658837 hasConcept C86554907 @default.
- W2802658837 hasConcept C86803240 @default.
- W2802658837 hasConcept C95444343 @default.
- W2802658837 hasConceptScore W2802658837C104317684 @default.